PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOteracil
Oteracil
Teysuno (oteracil) is a small molecule pharmaceutical. Oteracil was first approved as Teysuno on 2011-03-14. It has been approved in Europe to treat stomach neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
125 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16441191160
Pancreatic neoplasmsD010190EFO_0003860C2518—2—11
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230——2103—115
CarcinomaD002277—C80.0272——11
Esophageal neoplasmsD004938—C15162—19
Colorectal neoplasmsD015179——153——8
Squamous cell carcinomaD002294———61——7
Neoadjuvant therapyD020360———41——5
Non-small-cell lung carcinomaD002289——131——5
Esophageal squamous cell carcinomaD000077277———41——5
Colonic neoplasmsD003110—C18—31——4
Biliary tract neoplasmsD001661—C24.9—22—14
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8035——19
Rectal neoplasmsD012004——13——15
Liver neoplasmsD008113EFO_1001513C22.021———3
Gastrointestinal neoplasmsD005770—C26.9—2———2
Pancreatic ductal carcinomaD021441——11———2
Lung neoplasmsD008175HP_0100526C34.90—2———2
Squamous cell carcinoma of head and neckD000077195———2———2
ImmunotherapyD007167———2———2
Bile duct neoplasmsD001650———1———1
Unknown primary neoplasmsD009382———1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatocellular carcinomaD006528—C22.02————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CardiotoxicityD066126EFO_1001482—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOteracil
INNoteracil
Description
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.: 213 
Classification
Small molecule
Drug classuracil type antineoplastics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1nc(=O)[nH]c(=O)[nH]1
Identifiers
PDB—
CAS-ID937-13-3
RxCUI—
ChEMBL IDCHEMBL181932
ChEBI ID30863
PubChem CID54715158
DrugBankDB03209
UNII ID5VT6420TIG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,565 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,305 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use